Home Equities Score Vaxart, Inc. (VXRT) Stock Prices Skyrocket Following Announcement of T-cell Webinar

Vaxart, Inc. (VXRT) Stock Prices Skyrocket Following Announcement of T-cell Webinar

Vaxart, Inc. (VXRT) stock prices were up a staggering 37.46% as of market close on April 27th, 2021, bringing the price per share up to USD$8.33.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Novel COVID-19 Tablet

With the world hurtling towards COVID-19 solutions for the pandemic, VXRT is setting itself apart from its competitors with a drug, VXA-CoV2-1, that comes in tablet form rather than via injections. This circumvents the issue of the transportation of typical covid injections being a costly endeavor. Furthermore, it could facilitate the acceleration of universal immunizations because the administration of a tablet does not require specialized healthcare professionals in the way injections do.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Read More

Competitive Advantage of VXA-CoV2-1

Another massive differentiator of VXRT’s VXA-CoV2-1 is that it has the potential to be effective against the various strains of the COVID-19 virus that are emerging and are proving to be resistant to typical injection-based vaccinations. With the drug targeting nucleoprotein (N) as well as spike proteins (S), a significant T-cell response has been observed as a target of the N protein. This is significant because a potent T-cell response has the potential to offer protection against even more severe covid symptoms.

Additional Developments

So far, the drug has met its primary endpoint as well as all of its secondary endpoints in the first phase of its trial. VXRT has been collaborating with Kindred Biosciences for the manufacturing of various COVID-19 vaccine candidates, including VXA-CoV2-1. Under a recently expanded agreement, the plant located in California will see the scaling of clinical trial material into mid-size bioreactors. The agreement will also see the single-use bioreactors in the Kansas plant being used for manufacturing at a 2000L scale.

Agreement with Attwill

An agreement has also been entered with Attwill Vascular Technologies that will facilitate the processing and lyophilizing of specific compounds, as well as the tableting of the lyophilized compounds for use in VXA-CoV2-1. To capitalize on recent developments, the company has increased its workforce to 49 full-time employees, with hiring have been primarily conducted in R&D, clinical, regulatory manufacturing, and financial areas.

Promising Liquidity Position

December 31st, 2020 saw the company report cash and cash equivalents of USD$126.9 million, a monumental increase from the USD$13.5 million reported as of December 31st 2019. The healthy liquidity position is attributable to the USD$97 million netted from the company’s USD$100 million at-the-market facility from June 2020; the exercising of warrants, which netted VXRT USD$26 million; USD$9.2 having been raised from a registered direct offering in March 2020; and USD$4.9 million from VXRT’s USD$250 million at-the-market facility from October 2020.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for VXRT

The success of Phase 1 of VXA-CoV2-1’s clinical trial has boosted investor confidence, who continue to back the company as it gears up for Phase 2. With such promising results, partnerships to facilitate the hopeful commercial production of the drug, and a solid liquidity position, the company is poised to leverage its resources to come out ahead in the COVID-19 vaccine race. Both current and prospective shareholders are hopeful for the future of the company, as evidence by recent surges in VXRT stock prices.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Explains MOGO Stock Going Up Today?

The Mogo Inc. (NASDAQ: MOGO) stock has gained 5.04% to $8.55 in premarket trading today. Mogo stock finished last trading day at $8.14, down...

Zynga Inc. (ZNGA) stock rises in the Pre-Market: What’s going on?

Zynga Inc. (ZNGA) announced its first-quarter 2021 financial results after which the ZNGA stock happened to be green after underperformance in the last trade....

American Shared Hospital Services (AMS) Stock Continues to Soar Following Unprecedent Volumes Being Traded

American Shared Hospital Services (AMS) stock prices surged by 30.51% as of market close on May 5th, 2021, bringing the price per share up...

James River Group Holdings Ltd. (NASDAQ: JRVR) stock falls during pre-market. Why is it so?

James River Group Holdings Ltd. (NASDAQ: JRVR) stock plunged by 1.67% at last close while the JRVR stock continued decline by 25.74% at last...

Aviat Networks, Inc. (AVNW) Stock Trending Up After Promising Financial Reports for Most Recent Quarter

Aviat Networks, Inc. (AVNW) stock prices were up 3.81% as of market close on May 5th 2021, bringing the price per share up to...

Ambev S.A. (ABEV) Stock Trends Up Following Highly Promising Earnings Call for Q4 2020

Ambev S.A. (ABEV) stock prices were up 10.3943% shortly after the market opened on May 6th, 2021, bringing the price per share up to...

Sally Beauty Holdings (NYSE:SBH) stock surged in the current trading session; here’s why

In the current trading session, Sally Beauty Holdings Inc. (SBH) stock had surged by 19.69% to $24.25 at the time of writing. SBH stock...

Moderna Inc. (NASDAQ: MRNA) stock declines during current market. Let’s figure out why?

Moderna Inc. (NASDAQ: MRNA) stock falls by 5.31% in the current market trading after MRNA has announced its financial results for Q1 2021. Moderna...

Related News

Fastly, Inc. (NYSE: FSLY) stock plunged in the pre-market trading session: here’s why

Fastly, Inc. (NYSE: FSLY), a company specializing to provide real-time content delivery network services, which offers edge cloud platform, edge software development kit (SDK),...

What Is The Reason For GreenBox (GBOX) Stock Rallying In Pre-Market?

In premarket trading hours, GreenBox POS (NASDAQ: GBOX) rose 5.34% to $11.24 on the last check Thursday. GreenBox stock gained 1.81% to close at...

Why Is The HOME Stock Getting Raised In Pre-Hour Trades?

At last check, shares of At Home Group Inc. (NYSE: HOME) were up 14.90 percent to trade at $36.01 in premarket session today. The...

What Caused Nemaura (NMRD) To Rise Today In Premarket Session?

The shares of Nemaura Medical Inc. (NASDAQ: NMRD) were trading 12.12% higher at $12.4 before the bell at last check. Nemaura stock closed the...

Luokung Technology Corp. (LKCO) Stock Surges Amid China-U.S. Economic Tensions

Luokung Technology Corp. (LKCO) stock prices were down by 8.64% as of the market closing on May 5th, 2021, bringing the price per share...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.